Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DESLORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DESLORATADINE.
ACUVUE THERAVISION WITH KETOTIFEN vs DESLORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
5 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderate12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."